Skip to content
The Policy VaultThe Policy Vault

Krintafel (tafenoquine)Highmark

radical cure (prevention of relapse) of Plasmodium vivax malaria

Initial criteria

  • age ≥ 16 years
  • Diagnosis of Plasmodium vivax malaria (ICD-10: B51.9)
  • Krintafel will be used for treatment of malaria or radical cure
  • Krintafel will be used in combination with chloroquine or hydroxychloroquine

Approval duration

7 days (one-time authorization)